Literature DB >> 25724158

Role of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug.

Ajit S Narang1, Sherif Badawy, Qingmei Ye, Dhaval Patel, Maria Vincent, Krishnaswamy Raghavan, Yande Huang, Aaron Yamniuk, Balvinder Vig, John Crison, George Derbin, Yan Xu, Antonio Ramirez, Michael Galella, Frank A Rinaldi.   

Abstract

PURPOSE: Precipitation of weakly basic drugs in intestinal fluids can affect oral drug absorption. In this study, the implications of self-association of brivanib alaninate in acidic aqueous solution, leading to supersaturation at basic pH condition, on its solubility and oral absorption were investigated.
METHODS: Self-association of brivanib alaninate was investigated by proton NMR spectroscopy, surface tension measurement, dynamic light scattering, isothermal titration calorimetry, and molecular modeling. Drug solubility was determined in various pH media, and its tendency to supersaturate upon pH shift was investigated in buffered and biorelevant aqueous solutions. Pharmacokinetic modeling of human oral drug absorption was utilized for parameter sensitivity analyses of input variables.
RESULTS: Brivanib alaninate exhibited continuous, and pH- and concentration-dependent self-association. This phenomenon resulted in positive deviation of drug solubility at acidic pH and the formation of a stable supersaturated drug solution in pH-shift assays. Consistent with the supersaturation phenomenon observed in vitro, oral absorption simulations necessitated invoking long precipitation time in the intestine to successfully predict in vivo data.
CONCLUSIONS: Self-association of a weakly basic drug in acidic aqueous solution can increase its oral absorption by supersaturation and precipitation resistance at the intestinal pH. This consideration is important to the selection of parameters for oral absorption simulation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25724158     DOI: 10.1007/s11095-015-1645-y

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

Review 1.  In vitro methods to assess drug precipitation.

Authors:  Wei-Guo Dai
Journal:  Int J Pharm       Date:  2010-03-27       Impact factor: 5.875

2.  Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME).

Authors:  Wei-Guo Dai; Liang C Dong; Xinfeng Shi; Joe Nguyen; Juli Evans; Yaodong Xu; Abla A Creasey
Journal:  J Pharm Sci       Date:  2007-11       Impact factor: 3.534

Review 3.  Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?

Authors:  Joachim Brouwers; Marcus E Brewster; Patrick Augustijns
Journal:  J Pharm Sci       Date:  2009-08       Impact factor: 3.534

Review 4.  Impact of excipient interactions on drug bioavailability from solid dosage forms.

Authors:  Ravikiran Panakanti; Ajit S Narang
Journal:  Pharm Res       Date:  2012-05-19       Impact factor: 4.200

Review 5.  Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues.

Authors:  Jan Bevernage; Joachim Brouwers; Marcus E Brewster; Patrick Augustijns
Journal:  Int J Pharm       Date:  2012-11-27       Impact factor: 5.875

6.  Energetics of cyclodextrin-induced dissociation of insulin.

Authors:  M Lovatt; A Cooper; P Camilleri
Journal:  Eur Biophys J       Date:  1996       Impact factor: 1.733

7.  Quantitative analysis of the effect of supersaturation on in vivo drug absorption.

Authors:  Ryusuke Takano; Noriyuki Takata; Ryoichi Saito; Kentaro Furumoto; Shoichi Higo; Yoshiki Hayashi; Minoru Machida; Yoshinori Aso; Shinji Yamashita
Journal:  Mol Pharm       Date:  2010-08-12       Impact factor: 4.939

Review 8.  Brivanib alaninate for cancer.

Authors:  Ivan Diaz-Padilla; Lillian L Siu
Journal:  Expert Opin Investig Drugs       Date:  2011-03-11       Impact factor: 6.206

9.  Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study.

Authors:  Michael Kennedy; Jack Hu; Ping Gao; Lan Li; Alana Ali-Reynolds; Ben Chal; Vicki Gupta; Chandra Ma; Nidhi Mahajan; Anna Akrami; Sekhar Surapaneni
Journal:  Mol Pharm       Date:  2008 Nov-Dec       Impact factor: 4.939

10.  In vivo dog intestinal precipitation of mebendazole: a basic BCS class II drug.

Authors:  Sara Carlert; Pernilla Akesson; Gunilla Jerndal; Lennart Lindfors; Hans Lennernäs; Bertil Abrahamsson
Journal:  Mol Pharm       Date:  2012-09-21       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.